Loading…
Hosted by Jeff Martin · 🇺🇸 US · EN · 29 episodes
Established thought leaders with verified media credentials.
Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.
Jeff Martin hosts The Biotech Voyager, a news show with 29 episodes published.
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they become big news.
Welcome to The Biotech Voyager, the show that covers what's next in biotech.
Jack Gugel, co-founder and CEO of Arkana Therapeutics, joins the show to explain how a molecule discovered in Burmese python metabolism could offer an alternative to GLP-1 drugs, why pythons are the perfect model organis
Welcome to The Biotech Voyager. It's the show that covers the early-stage biotech space, uncovering the companies that are going to be a big deal in a couple of years.
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech. Drop a question in the chat to be part of the conversation .
Kevin Walton, CEO of Baseimmune, joins Ben and Jeff to break down one of the most underappreciated problems in modern medicine: fibrosis. IPF alone carries a life expectancy of three to five years upon diagnosis, and des
Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Feel free to leave a comment, and we will get to it as quickly as we can.
Jonathan Cohen-Gold, CEO of Houdini Bio, joins Ben and Jeff to break down one of the most underappreciated problems in cell and gene therapy: cells don't like foreign DNA. When you deliver a therapeutic gene, the cell's
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.
Wesley Wierson and Alex Abel founded Leah Labs seven years ago around a pets-first model. When generative biology arrived, they designed something that no existing investor would fund. Animal investors won't back human-s
The biggest unsolved problem in cell therapy is donor variability. Why one patient's cells work and another's fail is a question the field still cannot answer. Alex Ward and Caelan Anderson, co-founders of Tolemy Bio, ar
Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Today on the show: - 3 brand new startups in biotech that emerged from Stealth - 2 CEO interviews: one company is building a vaccine
This week, Innovian Space printed the first kidney and liver constructs in human history on the International Space Station. Jana Studemeier, CCO at Innovian Space, joins The Biotech Voyager to explain why gravity is the
Jay Kaplan, co-founder of Fractyl Health, joins The Biotech Voyager to explain why current GLP-1 drugs like Ozempic might have a worthy successor: a gene therapy that delivers GLP-1 directly to the pancreatic beta cells,
YouTube Description: Non-viral gene delivery has always had one fatal flaw: it couldn't get DNA into the nucleus efficiently. LNPs top out at around 5% nuclear entry. SonoThera just hit 50% using ultrasound. Co-founder K
Welcome to The Biotech Voyager. It's the live show that covers where the puck is going in biotech.
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.
Welcome to The Biotech Voyager - it's the show that covers what's next in biotech.
The Biotech Voyager is the show that covers what's next in biotech.
The live show that covers what's next in biotech. Join us live!
Kevin Walton
Baseimmune
1 appearance on this show
Jonathan Cohen-Gold
Houdini Bio
1 appearance on this show
Wesley Wierson
VelociTx
1 appearance on this show
Alex Ward
Tolemy Bio
1 appearance on this show
Jana Studemeier
Innovian Space
1 appearance on this show
Jay Kaplan
Fractyl Health
1 appearance on this show
Ken Greenberg
SonoThera
1 appearance on this show
the founders of Tolemy Bio
Tolemy Bio
1 appearance on this show
the founders of VelociTx
VelociTx
1 appearance on this show
Precede Bio
Precede Bio
1 appearance on this show
NanoMosaic
NanoMosaic
1 appearance on this show
John Boyce
28 Capital
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
The Biotech Voyager has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their news audience.
The Biotech Voyager is hosted by Jeff Martin. The show is categorised under news (commentary) and has published 29 episodes.
The Biotech Voyager has published 29 episodes.
The Biotech Voyager regularly covers news, commentary, science. It sits in the news category, with a commentary focus.
The Biotech Voyager is accessible for guests with genuine news expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Biotech Voyager hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Biotech Voyager average 74 minutes, giving guests a long-form format with plenty of time to expand on their expertise.
Our data rates The Biotech Voyager's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 3 days ago.